395 related articles for article (PubMed ID: 32279177)
1. Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort.
Quaranta MG; Ferrigno L; Monti M; Filomia R; Biliotti E; Iannone A; Migliorino G; Coco B; Morisco F; Vinci M; D'Ambrosio R; Chemello L; Massari M; Ieluzzi D; Russo FP; Blanc P; Verucchi G; Puoti M; Rumi MG; Barbaro F; Santantonio TA; Federico A; Chessa L; Gentile I; Zuin M; Parruti G; Morsica G; Kondili LA;
Hepatol Int; 2020 May; 14(3):362-372. PubMed ID: 32279177
[TBL] [Abstract][Full Text] [Related]
2. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
[TBL] [Abstract][Full Text] [Related]
3. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
[TBL] [Abstract][Full Text] [Related]
4. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
5. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
[TBL] [Abstract][Full Text] [Related]
6. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).
Quaranta MG; Cavalletto L; Russo FP; Calvaruso V; Ferrigno L; Zanetto A; Mattioli B; D'Ambrosio R; Panetta V; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Rosselli Del Turco E; Massari M; Licata A; Barbaro F; Persico M; Morisco F; Pompili M; Cerini F; Puoti M; Santantonio T; Craxì A; Kondili LA; Chemello L; On Behalf Of Piter Collaborating Investigators
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793565
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea.
Lim DH; Jeong JY; Nam S; Choi J; Kwon HC; Yoon YB; Kim Y; Chin B
J Korean Med Sci; 2021 Nov; 36(46):e308. PubMed ID: 34845874
[TBL] [Abstract][Full Text] [Related]
8. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
[TBL] [Abstract][Full Text] [Related]
9. Incidence of hepatocellular carcinoma in patients with chronic liver disease due to hepatitis B or C and coinfected with the human immunodeficiency virus: A retrospective cohort study.
Marcon PDS; Tovo CV; Kliemann DA; Fisch P; de Mattos AA
World J Gastroenterol; 2018 Feb; 24(5):613-622. PubMed ID: 29434450
[TBL] [Abstract][Full Text] [Related]
10. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
11. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals.
Corma-Gómez A; Morano L; Téllez F; Rivero-Juárez A; Real LM; Alados JC; Ríos-Villegas MJ; Vera-Méndez FJ; Muñoz RP; Geijo P; Macías J; Pineda JA;
AIDS; 2019 Jun; 33(7):1167-1174. PubMed ID: 30845068
[TBL] [Abstract][Full Text] [Related]
12. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
13. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis.
Merchante N; Rivero-Juárez A; Téllez F; Merino D; Ríos-Villegas MJ; Villalobos M; Omar M; Rincón P; Rivero A; Pérez-Pérez M; Raffo M; López-Montesinos I; Palacios R; Gómez-Vidal MA; Macías J; Pineda JA;
J Antimicrob Chemother; 2018 Sep; 73(9):2435-2443. PubMed ID: 29982683
[TBL] [Abstract][Full Text] [Related]
14. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
Kozbial K; Moser S; Al-Zoairy R; Schwarzer R; Datz C; Stauber R; Laferl H; Strasser M; Beinhardt S; Stättermayer AF; Gschwantler M; Zoller H; Maieron A; Graziadei I; Trauner M; Steindl-Munda P; Hofer H; Ferenci P
Liver Int; 2018 Jun; 38(6):1028-1035. PubMed ID: 29136329
[TBL] [Abstract][Full Text] [Related]
15. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
[TBL] [Abstract][Full Text] [Related]
16. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.
Lo Re V; Kallan MJ; Tate JP; Localio AR; Lim JK; Goetz MB; Klein MB; Rimland D; Rodriguez-Barradas MC; Butt AA; Gibert CL; Brown ST; Park L; Dubrow R; Reddy KR; Kostman JR; Strom BL; Justice AC
Ann Intern Med; 2014 Mar; 160(6):369-79. PubMed ID: 24723077
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
[TBL] [Abstract][Full Text] [Related]
19. Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Lacombe JM; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L; ; Martinez V
HIV Med; 2021 Nov; 22(10):924-935. PubMed ID: 34402547
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]